ZNF669 Inhibitors
ZNF669 inhibitors encompass a range of chemical compounds that, through their actions on various signaling pathways and molecular functions, lead to the diminished functional activity of ZNF669. Staurosporine and Alsterpaullone target kinase activities, with the former inhibiting a broad spectrum of kinases that may phosphorylate proteins interacting with ZNF669, thereby impacting its functionality. The latter, as a cyclin-dependent kinase inhibitor, could affect ZNF669's role in cell cycle regulation. Rapamycin and compounds like LY 294002 and Wortmannin work through the inhibition of the mTOR and PI3K pathways respectively. These actions could downregulate phosphorylation processes and AKT activity, leading to an indirect reduction of ZNF669's involvement in these pathways. Similarly, U0126 and PD 98059 inhibit the MEK/ERK pathway, SB 203580 targets the p38 MAPK, and SP600125 inhibits JNK, all of which could diminish the phosphorylation states of proteins that interact with ZNF669, reducing its functional activity.
Additionally, the activation of AMPK by AICAR may indirectly impact ZNF669 by altering energy homeostasis, which could influence ZNF669's role in cellular metabolism. Trichostatin A and 5-Azacytidine act on epigenetic mechanisms, the former by preventing histone deacetylation and the latter by inhibiting DNA methylation. These changes in chromatin structure and gene expression could affect the regulatory functions of ZNF669, leading to a downstream decrease in its activity. Collectively, these inhibitors operate through distinct mechanisms to collectively converge on the functional suppression of ZNF669, effectively reducing its activity without directly altering its expression or translation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor that indirectly diminishes ZNF669 activity by inhibiting kinases that phosphorylate proteins, potentially impacting the protein-protein interactions in which ZNF669 is involved. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin could suppress mTORC1-mediated phosphorylation events, thereby indirectly reducing the potential for ZNF669 to be involved in protein translation regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 inhibits PI3K, leading to a decrease in AKT phosphorylation, which could affect the signaling pathways where ZNF669 may play a regulatory role, consequently leading to its functional inhibition. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that could impede the ERK pathway, potentially diminishing the post-translational modifications of proteins that interact with ZNF669, leading to an indirect decrease in ZNF669 functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor, and by inhibiting p38 MAPK, it may affect the phosphorylation status of proteins interacting with ZNF669, indirectly reducing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that can lead to diminished AKT activity and may therefore reduce the functional involvement of ZNF669 in associated signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that can decrease ERK pathway activity, potentially resulting in diminished functional activity of ZNF669 by affecting its protein interaction network. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As a JNK inhibitor, SP600125 could reduce the activity of the JNK pathway, potentially touching upon the functional activity of ZNF669 if it is involved in related stress response pathways. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which might indirectly reduce ZNF669 activity by modifying energy homeostasis and phosphorylation states affecting ZNF669's role in cellular metabolism. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, could lead to changes in chromatin structure affecting the transcriptional regulation where ZNF669 might be implicated, thus indirectly diminishing its activity. | ||||||